West Pharmaceutical Services Stock Cash Flow From Operations

WST Stock

USD 331.40 0.00 0.00%

West Pharmaceutical Services fundamentals help investors to digest information that contributes to West Pharmaceutical's financial success or failures. It also enables traders to predict the movement of West Stock. The fundamental analysis module provides a way to measure West Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to West Pharmaceutical stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

West Pharmaceutical Services Company Cash Flow From Operations Analysis

West Pharmaceutical's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current West Pharmaceutical Cash Flow From Operations

776.5 M

Most of West Pharmaceutical's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, West Pharmaceutical Services is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

West Cash Flow From Operations Driver Correlations

Understanding the fundamental principles of building solid financial models for West Pharmaceutical is extremely important. It helps to project a fair market value of West Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since West Pharmaceutical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of West Pharmaceutical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of West Pharmaceutical's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.98	-0.87	0.97	0.98	0.76	0.99	0.65	-0.35	0.98	0.54	-0.56	0.47	-0.86	0.97	0.15	0.87	0.95	-0.61	0.53	0.61	0.81	-0.91	0.52	0.86	0.9	0.89	-0.62
Total Stockholder Equity	0.98		-0.93	0.99	0.99	0.66	0.99	0.65	-0.5	0.97	0.55	-0.68	0.36	-0.91	0.97	0.05	0.87	0.99	-0.69	0.59	0.59	0.82	-0.95	0.52	0.88	0.91	0.91	-0.64
Net Debt	-0.87	-0.93		-0.93	-0.92	-0.5	-0.93	-0.54	0.71	-0.87	-0.48	0.77	-0.06	0.96	-0.84	0.08	-0.86	-0.95	0.71	-0.59	-0.65	-0.84	0.93	-0.44	-0.91	-0.93	-0.94	0.54
Retained Earnings	0.97	0.99	-0.93		0.97	0.66	0.98	0.71	-0.51	0.94	0.47	-0.72	0.3	-0.92	0.97	0.06	0.87	1.0	-0.64	0.52	0.6	0.77	-0.9	0.61	0.88	0.92	0.91	-0.72
Net Receivables	0.98	0.99	-0.92	0.97		0.71	0.99	0.59	-0.45	0.98	0.56	-0.61	0.41	-0.9	0.96	0.11	0.88	0.96	-0.66	0.59	0.63	0.86	-0.96	0.44	0.89	0.91	0.92	-0.57
Total Liab	0.76	0.66	-0.5	0.66	0.71		0.73	0.38	0.13	0.72	0.16	-0.06	0.51	-0.56	0.65	0.68	0.77	0.63	0.02	-0.01	0.73	0.68	-0.57	0.37	0.67	0.7	0.69	-0.4
Total Current Assets	0.99	0.99	-0.93	0.98	0.99	0.73		0.61	-0.44	0.97	0.53	-0.62	0.38	-0.91	0.96	0.13	0.89	0.97	-0.63	0.54	0.65	0.84	-0.94	0.5	0.9	0.93	0.94	-0.6
Short Term Debt	0.65	0.65	-0.54	0.71	0.59	0.38	0.61		-0.33	0.61	0.15	-0.71	0.16	-0.58	0.7	-0.06	0.49	0.69	-0.42	0.25	0.31	0.29	-0.46	0.86	0.48	0.56	0.47	-0.82
Intangible Assets	-0.35	-0.5	0.71	-0.51	-0.45	0.13	-0.44	-0.33		-0.37	-0.16	0.85	0.52	0.69	-0.38	0.48	-0.46	-0.58	0.6	-0.51	-0.28	-0.43	0.54	-0.24	-0.5	-0.51	-0.52	0.4
Accounts Payable	0.98	0.97	-0.87	0.94	0.98	0.72	0.97	0.61	-0.37		0.6	-0.57	0.49	-0.83	0.96	0.11	0.86	0.93	-0.65	0.62	0.61	0.84	-0.94	0.46	0.85	0.86	0.86	-0.57
Common Stock	0.54	0.55	-0.48	0.47	0.56	0.16	0.53	0.15	-0.16	0.6		-0.24	0.59	-0.32	0.6	-0.26	0.33	0.46	-0.76	0.84	0.09	0.54	-0.63	0.0	0.46	0.4	0.4	0.0
Long Term Debt	-0.56	-0.68	0.77	-0.72	-0.61	-0.06	-0.62	-0.71	0.85	-0.57	-0.24		0.25	0.75	-0.62	0.45	-0.56	-0.76	0.69	-0.53	-0.32	-0.45	0.62	-0.61	-0.59	-0.63	-0.59	0.7
Good Will	0.47	0.36	-0.06	0.3	0.41	0.51	0.38	0.16	0.52	0.49	0.59	0.25		-0.03	0.5	0.34	0.16	0.23	-0.22	0.33	0.07	0.28	-0.34	0.0	0.19	0.17	0.18	-0.01
Treasury Stock	-0.86	-0.91	0.96	-0.92	-0.9	-0.56	-0.91	-0.58	0.69	-0.83	-0.32	0.75	-0.03		-0.82	-0.06	-0.86	-0.95	0.57	-0.45	-0.71	-0.8	0.88	-0.44	-0.92	-0.95	-0.95	0.58
Property Plant Equipment	0.97	0.97	-0.84	0.97	0.96	0.65	0.96	0.7	-0.38	0.96	0.6	-0.62	0.5	-0.82		0.07	0.78	0.95	-0.68	0.61	0.49	0.72	-0.89	0.55	0.79	0.83	0.81	-0.68
Current Deferred Revenue	0.15	0.05	0.08	0.06	0.11	0.68	0.13	-0.06	0.48	0.11	-0.26	0.45	0.34	-0.06	0.07		0.15	0.03	0.6	-0.54	0.53	0.1	0.04	0.01	0.16	0.18	0.18	0.02
Short Term Investments	0.87	0.87	-0.86	0.87	0.88	0.77	0.89	0.49	-0.46	0.86	0.33	-0.56	0.16	-0.86	0.78	0.15		0.88	-0.42	0.4	0.72	0.92	-0.85	0.43	0.87	0.89	0.89	-0.54
Net Tangible Assets	0.95	0.99	-0.95	1.0	0.96	0.63	0.97	0.69	-0.58	0.93	0.46	-0.76	0.23	-0.95	0.95	0.03	0.88		-0.65	0.53	0.62	0.79	-0.91	0.59	0.89	0.93	0.91	-0.71
Long Term Debt Total	-0.61	-0.69	0.71	-0.64	-0.66	0.02	-0.63	-0.42	0.6	-0.65	-0.76	0.69	-0.22	0.57	-0.68	0.6	-0.42	-0.65		-0.92	-0.05	-0.53	0.75	-0.22	-0.53	-0.52	-0.53	0.3
Capital Surpluse	0.53	0.59	-0.59	0.52	0.59	-0.01	0.54	0.25	-0.51	0.62	0.84	-0.53	0.33	-0.45	0.61	-0.54	0.4	0.53	-0.92		0.03	0.58	-0.73	-0.01	0.45	0.39	0.41	-0.14
Deferred Long Term Liab	0.61	0.59	-0.65	0.6	0.63	0.73	0.65	0.31	-0.28	0.61	0.09	-0.32	0.07	-0.71	0.49	0.53	0.72	0.62	-0.05	0.03		0.74	-0.56	0.29	0.82	0.8	0.79	-0.22
Long Term Investments	0.81	0.82	-0.84	0.77	0.86	0.68	0.84	0.29	-0.43	0.84	0.54	-0.45	0.28	-0.8	0.72	0.1	0.92	0.79	-0.53	0.58	0.74		-0.89	0.15	0.91	0.85	0.87	-0.23
Accumulated Depreciation	-0.91	-0.95	0.93	-0.9	-0.96	-0.57	-0.94	-0.46	0.54	-0.94	-0.63	0.62	-0.34	0.88	-0.89	0.04	-0.85	-0.91	0.75	-0.73	-0.56	-0.89		-0.26	-0.86	-0.85	-0.88	0.43
Short Long Term Debt	0.52	0.52	-0.44	0.61	0.44	0.37	0.5	0.86	-0.24	0.46	0.0	-0.61	0.0	-0.44	0.55	0.01	0.43	0.59	-0.22	-0.01	0.29	0.15	-0.26		0.39	0.5	0.39	-0.86
Cash And Equivalents	0.86	0.88	-0.91	0.88	0.89	0.67	0.9	0.48	-0.5	0.85	0.46	-0.59	0.19	-0.92	0.79	0.16	0.87	0.89	-0.53	0.45	0.82	0.91	-0.86	0.39		0.98	0.98	-0.39
Net Invested Capital	0.9	0.91	-0.93	0.92	0.91	0.7	0.93	0.56	-0.51	0.86	0.4	-0.63	0.17	-0.95	0.83	0.18	0.89	0.93	-0.52	0.39	0.8	0.85	-0.85	0.5	0.98		0.99	-0.51
Net Working Capital	0.89	0.91	-0.94	0.91	0.92	0.69	0.94	0.47	-0.52	0.86	0.4	-0.59	0.18	-0.95	0.81	0.18	0.89	0.91	-0.53	0.41	0.79	0.87	-0.88	0.39	0.98	0.99		-0.44
Capital Stock	-0.62	-0.64	0.54	-0.72	-0.57	-0.4	-0.6	-0.82	0.4	-0.57	0.0	0.7	-0.01	0.58	-0.68	0.02	-0.54	-0.71	0.3	-0.14	-0.22	-0.23	0.43	-0.86	-0.39	-0.51	-0.44

Click cells to compare fundamentals

West Cash Flow From Operations Historical Pattern

Today, most investors in West Pharmaceutical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various West Pharmaceutical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash flow from operations growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of West Pharmaceutical cash flow from operations as a starting point in their analysis.

West Pharmaceutical Cash Flow From Operations

Timeline

Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Competition

Predict West Pharmaceutical

Total Cash From Operating Activities Over Time

In accordance with the recently published financial statements, West Pharmaceutical Services has 776.5 M in Cash Flow From Operations. This is 47.27% higher than that of the Health Care Equipment & Supplies sector and 192.72% higher than that of the Health Care industry. The cash flow from operations for all United States stocks is 20.05% higher than that of the company.

West Cash Flow From Operations Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses West Pharmaceutical's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of West Pharmaceutical could also be used in its relative valuation, which is a method of valuing West Pharmaceutical by comparing valuation metrics of similar companies.

West Pharmaceutical is currently under evaluation in cash flow from operations category among its peers.

West Pharmaceutical ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, West Pharmaceutical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to West Pharmaceutical's managers, analysts, and investors.

Environmental

Governance

Social

West Fundamentals

	Return On Equity	0.18
	Return On Asset	0.1
	Profit Margin	0.17 %
	Operating Margin	0.22 %
	Current Valuation	23.81 B
	Shares Outstanding	72.42 M
	Shares Owned By Insiders	0.58 %
	Shares Owned By Institutions	96.62 %
	Number Of Shares Shorted	1.16 M
	Price To Earning	40.71 X
	Price To Book	8.72 X
	Price To Sales	8.34 X
	Revenue	2.95 B
	Gross Profit	1.14 B
	EBITDA	844.1 M
	Net Income	593.4 M
	Cash And Equivalents	894.3 M
	Cash Per Share	9.85 X
	Total Debt	309 M
	Debt To Equity	0.12 %
	Current Ratio	3.80 X
	Book Value Per Share	37.96 X
	Cash Flow From Operations	776.5 M
	Short Ratio	1.86 X
	Earnings Per Share	6.73 X
	Price To Earnings To Growth	6.19 X
	Target Price	371.01
	Number Of Employees	10.6 K
	Beta	1.0
	Market Capitalization	24 B
	Total Asset	3.83 B
	Retained Earnings	3.52 B
	Working Capital	1.26 B
	Current Asset	673.7 M
	Current Liabilities	314.3 M
	Annual Yield	0 %
	Five Year Return	0.36 %
	Net Asset	3.83 B
	Last Dividend Paid	0.8

About West Pharmaceutical Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze West Pharmaceutical Services's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of West Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of West Pharmaceutical Services based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for West Stock Analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC